Meeting
2018 ASCO Annual Meeting
PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer.
Authors
Charlie Gourley
University of Edinburgh Cancer Research UK Centre, MRC IGMM, Edinburgh, United Kingdom
Charlie Gourley , Heather J. Dalton , Susana N. Banerjee , Joseph Buscema , Michelle Lockley , Jonathan Krell , Bradley J. Monk
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT03146663
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS5612)
DOI
10.1200/JCO.2018.36.15_suppl.TPS5612
Abstract #
TPS5612
Poster Bd #
333a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.
First Author: Kathleen N. Moore
Poster
2015 ASCO Annual Meeting
Multicenter randomized Phase II study of AZD1775 plus chemotherapy versus chemotherapy alone in patients with platinum-resistant TP53-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer.
First Author: Kathleen N. Moore
Poster
2014 ASCO Annual Meeting
Pertuzumab (P) plus chemotherapy (CT) for platinum-resistant ovarian cancer: Safety run-in results of the PENELOPE trial.
First Author: Antonio Gonzalez-Martin
Poster
2019 ASCO Annual Meeting
Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208).
First Author: Haider Mahdi